Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Nashville Biosciences Blood Sample Collection Study

Multiple Cancer Types

Colon, Liver, Lung, Non Small Cell, Ovarian, Pancreatic, Rectal
N/A
Bernard, Gordon
VICCMD18123

Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Multiple Cancer Types

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).
Lung, Non Small Cell
II
Horn, Leora
NCT03539536
VICCTHO18125

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and / or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Breast

This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and / or metastatic breast cancer subjects previously treated with trastuzumab and taxane.
Breast
III
Rexer, Brent
NCT03529110
VICCBRE18126

Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian / Tubal Tissue to Determine Presence of Malignancy

Gynecologic

Prospective, multi-center, non-randomized study to assess the ability of the Cytuity device to collect cell samples from the fallopian tube that can be evaluated for the presence or absence of malignancy.
Gynecologic
N/A
Anderson, Ted
NCT03593681
VICCGYN18131

Provision of Free Varenicline (Chantix) within the Context of a Dedicated Outpatient Tobacco Treatment Clinic (TTC) for Cancer Patients

Lung

Lung
N/A
Tindle, Hilary
VICCTHO18132

A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia

Leukemia

Leukemia
I/II
Byrne, Michael
NCT03624036
VICCBMT18134

M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

Lung

The study will evaluate M7824 monotherapy versus pembrolizumab as 1L treatment for participants with advanced NSCLC with high PD-L1-tumor expression.
Lung
II
Iams, Wade
NCT03631706
VICCTHO18139

Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma

Lymphoma

The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in participants with high-risk large B-cell lymphoma.
Lymphoma
II
Oluwole, Olalekan
NCT03761056
VICCBMT18146

Testing AZD1775 in Advanced Solid Tumors that have a Mutation called SETD2

Miscellaneous

This phase II trial studies how well adavosertib works in treating patients with SETD2-deficient solid tumors that have spread to other places in the body (advanced / metastatic). Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Miscellaneous
II
Rathmell, Kim
NCT03284385
VICCURO18153ET-CT

Fluid Measurements and MRI in Determining Biomarkers of Lymphatic Dysfunction in Patients with Breast Cancer

Breast

This trial uses fluid measurements of the arm and MRI to determine biomarkers of lymphatic dysfunction in patients with breast cancer. Studying the lymphatic system (the part of your body that helps to process and clear waste products) in different ways will help doctors understand more about lymphedema (excess fluid after lymph nodes are removed) and help with prevention and management of lymphedema in patients with breast cancer.
Breast
N/A
Donahue, Manus
NCT03760744
VICCBRE18156

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: